NCT04937543View on ClinicalTrials.gov

Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

October 30, 2021

Study Completion Date

May 20, 2022

Conditions
Covid19
Interventions
DRUG

inhaled beclametasone

Adding belcamethasone to standard of care for Covid 19 positive patients

DRUG

Inahaled beclomethasone / formoterol / glycopyrronium

Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients

Trial Locations (1)

18618687

Hospital das Clínicas da Faculdade de Medicina de Botucatu, Botucatu

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

UPECLIN HC FM Botucatu Unesp

OTHER